NetScientific PLC - London-based deep tech and life sciences-focused venture capital investment company - Reports that its portfolio company, PDS Biotechnology Corp, has announced updated interim data from the Versatile-002 phase two clinical trial evaluating PDS0101 in combination with Merck & Co Inc's Keytruda in patients with unresectable, recurrent, or metastatic HPV16-positive head and neck squamous cell carcinoma.
"The updated interim data from our VERSATILE-002 clinical trial further validates the potential of PDS0101 when combined with Keytruda to address the urgent need for more effective therapies that are well tolerated and allow advanced recurrent and metastatic HPV16-positive head and neck cancer patients to live significantly longer lives than current approaches. Following feedback from the FDA, we look forward to evaluating this promising combination treatment in the Versatile-003 Phase 3 clinical trial, which we expect to initiate in the fourth quarter of 2023," says PDS Biotech Chief Executive Frank Bedu-Addo.
Versatile-003 will investigate the efficacy and safety of PDS0101 combined with Keytruda compared to Keytruda monotherapy in ICI-naive patients with recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma.
Current stock price: 60.22 pence
12-month change: up 22%
By Heather Rydings, Alliance News senior economics reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Netscientific (NSCI)